Effect of potent P2Y12 inhibitor monotherapy after double antiplatelet therapy for 1 month after PCI in ACS patients

Not Applicable

• Conditions: Diseases of the circulatory system

• Registration Number: KCT0006861
• Lead Sponsor: Chonnam National University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

1) Adults 19 years of age or older
2) Acute coronary patients who had successful percutaneous coronary intervention (PCI) with Orsiro Mission® stent
3) Subjects who agree to the research protocol and clinical follow-up plan, decide voluntarily to participate in this clinical study, and agree in writing to the subject consent form

Exclusion Criteria

1) Subjects with known hypersensitivity or contraindication to the following drugs or substances: heparin, aspirin, prasugrel, ticagrelor, sirolimus, contrast agent
2) If you are taking anticoagulants: warfarin, apixaban, rivaroxaban, dabigatran, edoxaban
3) In case of previous myocardial infarction or coronary artery revascularization (percutaneous coronary intervention or coronary artery bypass surgery)
4) Subjects with a transient ischemic attack (TIA) or stroke
5) Subjects of fertile age who are planning to become pregnant or cannot rule out the possibility of pregnancy during the study period
6) Subjects whose remaining life expectancy is less than 1 year
7) Subjects who visited the hospital due to cardiac arrest or psychogenic shock and whose survival is predicted to be low by medical judgment
8) Complex lesions – unprotected left main lesions, chronic obstructive lesions, severely calcified or tortuous lesions
9) You are participating in another randomized controlled study, or you are participating in an observational study that may affect the study.
10) In case the researcher judges that it is not suitable for this clinical study or may increase the risk related to research participation
11) Patients with severe renal and hepatic dysfunction including hemodialysis patients and cirrhosis patients

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
cardiac death, nonfatal myocardial Infarction, ischemia-driven target vessel revascularization, stroke, or major bleeding (BARC criteria 3 )

Secondary Outcome Measures

Name	Time	Method
Gather information on any injuries or complications that may be related to the procedure.